Research Coverage of Japanese Listed Companies, Shared Research Inc

Shared Research

Research Coverage of Japanese Listed Companies

Shared Research Inc

Pioneering research coverage of Japanese listed companies. Now customizable and interactive for global institutional investors. Corporate access reimagined.

Equity Bottom-Up

Symbio Pharmaceuticals / Equity Bottom-Up

<ul><li>Sales dropped 55.8% YoY to JPY264mn due to generic competition and inventory adjustments ahead of drug price revision.</li><li>SG&A expenses rose 7.3% YoY to JPY1.4bn, including R&D expenses of JPY819mn, up 18.5% YoY.</li><li>Operating loss was JPY1.2bn, compared to a loss of JPY807mn in Q1 FY12/24, with maintained full-year forecast.</li></ul>

Sales dropped 55.8% YoY to JPY264mn due to generic competition and inventory adjustments ahead of drug price revision.SG&A expenses rose 7.3% YoY to JPY1.4bn, including R&D expenses of JPY819mn, up 18.5% YoY.Operating loss was JPY1.2bn, compared to a loss of JPY807mn in Q1 FY12/24, with maintained full-year forecast.

Symbio Pharmaceuticals (4582 JP): Q1 FY12/25 flash update

<ul><li>Sales decreased by 56.1% YoY to JPY2.5bn, with a gross profit of JPY1.9bn and a gross margin of 76.4%.</li><li>Operating loss increased to JPY3.9bn in FY12/24, with SG&A expenses at JPY5.8bn, including R&D expenses of JPY3.4bn.</li><li>FY12/25 forecast: Sales at JPY1.9bn, operating loss at JPY4.3bn, with total SG&A expenses projected at JPY5.6bn.</li></ul>

Sales decreased by 56.1% YoY to JPY2.5bn, with a gross profit of JPY1.9bn and a gross margin of 76.4%.Operating loss increased to JPY3.9bn in FY12/24, with SG&A expenses at JPY5.8bn, including R&D expenses of JPY3.4bn.FY12/25 forecast: Sales at JPY1.9bn, operating loss at JPY4.3bn, with total SG&A expenses projected at JPY5.6bn.

Symbio Pharmaceuticals (4582 JP): Full-year FY12/24 flash update

<ul><li>Sales decreased by 57.1% YoY to JPY1.9bn, with operating, recurring, and net losses each at JPY2.8bn.</li><li>SG&A expenses increased by 12.7% YoY to JPY4.2bn, with R&D expenses rising 36.7% YoY to JPY2.5bn.</li><li>The company revised its FY12/24 forecast, projecting a full-year operating loss of JPY3.7bn and net loss of JPY3.6bn.</li></ul>

Sales decreased by 57.1% YoY to JPY1.9bn, with operating, recurring, and net losses each at JPY2.8bn.SG&A expenses increased by 12.7% YoY to JPY4.2bn, with R&D expenses rising 36.7% YoY to JPY2.5bn.The company revised its FY12/24 forecast, projecting a full-year operating loss of JPY3.7bn and net loss of JPY3.6bn.

Symbio Pharmaceuticals (4582 JP): Q3 FY12/24 flash update

<ul><li>Sales decreased by 59.6% YoY to JPY1.3bn, with a gross profit of JPY996mn and a gross profit margin of 77.6%.</li><li>Operating loss was JPY1.7bn, recurring loss JPY1.5bn, and net loss attributable to owners of the parent JPY1.5bn.</li><li>SG&A expenses were JPY2.7bn (+7.6% YoY), with R&D expenses amounting to JPY1.5bn (+27.2% YoY).</li></ul>

Sales decreased by 59.6% YoY to JPY1.3bn, with a gross profit of JPY996mn and a gross profit margin of 77.6%.Operating loss was JPY1.7bn, recurring loss JPY1.5bn, and net loss attributable to owners of the parent JPY1.5bn.SG&A expenses were JPY2.7bn (+7.6% YoY), with R&D expenses amounting to JPY1.5bn (+27.2% YoY).

Symbio Pharmaceuticals (4582 JP): 1H FY12/24 flash update

Leading International Investment Research, Edison Investment Research

Edison Investment Research

Leading International Investment Research

Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.

<p>Edison Investment Research is terminating coverage on Brooge Energy (BROG), Tyman (TYMN), SymBio Pharmaceuticals (4582), Aspire Global (0EAZ), CiiTECH and Marshall Motor Holdings (MMH). Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant.</p>

Edison Investment Research is terminating coverage on Brooge Energy (BROG), Tyman (TYMN), SymBio Pharmaceuticals (4582), Aspire Global (0EAZ), CiiTECH and Marshall Motor Holdings (MMH). Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant.

SymBio Pharmaceuticals - Termination of coverage

Japan

Symbio Pharmaceuticals Limited develops and commercializes prescription drugs n oncology, hematology and auto-immune disease for Japan and other Asia Pacific markets.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Symbio Pharmaceuticals (4582 JP)